The Priority Review

Tag

Upadacitinib

1 story

  1. Clinical trials

    AbbVie registers Phase 3 trial of upadacitinib in pediatric non-segmental vitiligo

    The study will enroll approximately 154 participants aged 6 to <12 years and is expected to start on January 28, 2027. It is to evaluate the efficacy, safety, and tolerability of upadacitinib over 48 weeks of treatment followed by 112 weeks of continued blinded therapy.